Therapeutics of vein graft intimal hyperplasia: 100 years on.
Intimal hyperplasia is central to the pathology of vein graft re-stenosis, and despite considerable advances in our understanding of vascular biology since it was first described 100 years ago, it is still a significant clinical problem. Recent decades have seen the development of many new therapeutic agents aimed at treating this condition, but the successes of laboratory studies have not been replicated in the clinic yet. This review discusses these therapeutic agents, how their modes of action relate to the pathogenesis of vein graft intimal hyperplasia, and considerations of ways in which such therapy may be improved in the future.
Wallitt
Edward J W
EJ
Department of Cardiothoracic Surgery, Imperial College, London, United Kingdom.
Jevon
Marc
M
Hornick
Philip I
PI
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology; D049109:Cell Proliferation; D001026:Coronary Artery Bypass / Q000009:adverse effects; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006965:Hyperplasia; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012501:Saphenous Vein / Q000637:transplantation; D033081:Shear Strength; D020123:Sirolimus / Q000627:therapeutic use; D013314:Stress, Mechanical; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology*; D014654:Vascular Patency; D014680:Veins / Q000637:transplantation*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus